Bausch Health Companies Inc. (BHC) – Divest assets to improve capital structure

in Company Report, Healthcare & Life Sciences, Pharma & Biotech on December 31, 2021

BHC experienced statistically significant top-line results from the second Phase III trial for NOV03
in dry eye disease associated with meibomian gland dysfunction. It also received FDA approval of XIPERE, which it expect to launch in Q1FY22.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– DCF Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 35

Release Information

  • Released
    :

    December 31, 2021

  • Last Updated
    :

    January 5, 2022